P622: Network meta-analysis comparing efficacy between biologics and conventional therapies to prevent endoscopic postoperative recurrence in patients with Crohn@E@s diseaseECCO'24Year: 2024
Authors: Hupé, M.(1)*;Pereira, B.(2);Mathieu, N.(1);Buisson, A.(3);
(1)CHU Grenoble, IBD Unit, Grenoble, France;(2)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(3)CHU Clermont Ferrand, IBD Unit, Clermont-Ferrand, France;
P623: Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s diseaseECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Danese, S.(2);Colombel, J.F.(3);Hisamatsu, T.(4);Irving, P.M.(5,6);Park, H.(7);Kim, D.H.(7);Lee, Y.N.(7);Hanauer, S.B.(8);
(1)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(2)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(3)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(5)Guy’s and St Thomas’ Hospital, Department of Gastroenterology, London, United Kingdom;(6)King@E@s College London, School of Immunology and Microbial Sciences, London, United Kingdom;(7)Celltrion Healthcare Co.- Ltd, Not applicable, Incheon, Korea- Republic Of;(8)Northwestern University- Feinberg School of Medicine, Department of Gastroenterology and Hepatology, Chicago, United States;
P625: Electronic patient-reported outcomes in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional German LISTEN II studyECCO'24Year: 2024
Authors: Teich, N.(1)*;Stallmach , A.(2);Schulze, H.(3);Cavlar, T.(4);Knop , J.(4);Henneberger, S.(5);
(1)Group Practice in Internal Medicine, Digestive and Metabolic Diseases, Leipzig, Germany;(2)University Hospital Jena, Clinic for Internal Medicine IV, Jena, Germany;(3)AGAPLESION Markus-Hospital, Medical Clinic I, Frankfurt am Main, Germany;(4)Takeda Pharma Vertrieb GmbH & Co. KG, Medical Affairs, Berlin, Germany;(5)Emmes Biopharma Germany GmbH, Project Management, Munich, Germany;
P626: JNJ-77242113, an oral peptide selectively targeting the IL-23 receptor, demonstrates pharmacodynamic activity in rat and human colon tissue explants following oral dosingECCO'24Year: 2024
Authors: de Leon-Tabaldo, A.(1);Strawn, D.(2);Chang, L.(1);Cheng, X.(3);Greving, C.(1);Knight, B.(1);Sendecki, J.(2);Sherlock, J.(2);Modi, N.B.(3);Kannan, A.(2);Fourie, A.(1)*;
(1)Janssen, Research & Development, La Jolla, United States;(2)Janssen, Research & Development, Spring House, United States;(3)Protagonist Therapeutics, Research & Development, Newark, United States;
P627: Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease by disease location: Results from the EVOLVE Expansion studyECCO'24Year: 2024
Authors: Scharl, M.(1);Christensen, B.(2,3);Bressler, B.(4);Brett, N.R.(5);Gianchetti, L.(6);Kamble, P.(7);Adsul, S.(8);Farhat, Z.(7);Ferrante, M.(9)*;
(1)University Hospital Zurich- University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;(2)The Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(3)The University of Melbourne, Department of Medicine, Melbourne, Australia;(4)St. Paul’s Hospital, Division of Gastroenterology, Vancouver, Canada;(5)PPD- part of Thermo Fisher Scientific, Epidemiology and Scientific Affairs- PPAS and RWE, Montreal, Canada;(6)PPD- part of Thermo Fisher Scientific, Epidemiology and Scientific Affairs- PPAS and RWE, Philadelphia, United States;(7)Takeda Pharmaceuticals, Global Evidence & Outcomes - Gastroenterology, Cambridge, United States;(8)Takeda Pharmaceuticals, Global Medical Unit, Cambridge, United States;(9)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P628: Vedolizumab in Indian patients with Inflammatory Bowel Disease: Interim results from a prospective, multicentre, open-label, phase 4 studyECCO'24Year: 2024
Authors: Kabrawala, M.(1);Banerjee, R.(2)*;Ahuja, V.(3);Anumula, K.(4);Bharadwaj, V.(5);Dalal, A.(6);Ramesh Kumar, B.(7);Mukewar, S.(8);Sood, A.(9);Prasad, V.M.(10);Arora, S.(11);Kirde, S.(11);Sharma, N.(11);
(1)Surat Institute of Digestive Science- SIDS Hospital, Department of Gastroenterology, Surat, India;(2)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;(3)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(4)Government General Hospital, Department of Gastroenterology, Guntur, India;(5)Dr. Ram Manohar Lohia Hospital, Department of Gastroenterology, New Delhi, India;(6)Maulana Azad Medical College & Associated G B Pant Hospital, Department of Gastroenterology, New Delhi, India;(7)Osmania Medical College & General Hospital, Department of Gastroenterology, Hyderabad, India;(8)Midas Multi-Specialty Hospital, Department of Gastroenterology, Nagpur, India;(9)Dayanand Medical College and Hospital, Department of Gastroenterology, Ludhiana, India;(10)VGM Hospital, Institute of Gastroenterology, Coimbatore, India;(11)Takeda Biopharmaceuticals India Private Limited, Medical affairs, Gurgaon, India;
P629: JAK inhibitor safety in Inflammatory Bowel Disease: real-world data comparing the effect of JAK inhibitors on blood parameters and their clinical significanceECCO'24Year: 2024
Authors: Radia , C.(1);George , R.(1)*;Campbell , S.(1);Abdel-Aziz , S.(1);Plewa , S.(1);Ratcliff , S.(1);Blake , T.(1);Medcalf , L.(1);Patel , M.(1);Dubois , P.(1);Pavlidis , P.(1);Kent , A.J.(1);
(1)King’s College Hospital NHS Foundation Trust, Gastroenterology, London, United Kingdom;
P630: Identification of specific cell subsets related to treatment response after anti-tumor necrosis factor use in Korean ulcerative colitis patients using single cell RNA sequencing: a preliminary studyECCO'24Year: 2024
Authors: Shin, S.R.(1)*;Jeon, S.R.(1);Jung, Y.H.(2);Kim, H.G.(1);Kim, J.O.(1);Choi, S.(2);Ko, B.M.(1);Lee, W.M.(1);Hwang, W.C.(3);
(1)Soonchunhyang University College of Medicine, Institute of Digestive Research- Digestive Disease Center, Seoul, Korea- Republic Of;(2)Soonchunhyang University College of Medicine, Department of Gastroenterology, Cheonan, Korea- Republic Of;(3)Hanyang Institute of Bioscience and Biotechnology, Department of Pre‑Medicine- College of Medicine- Graduate School of Biomedical Science and Engineering, Seoul, Korea- Republic Of;
P631: Effectiveness of Early Thiopurine Use in Korean Patients with Moderate-to-Severe Ulcerative Colitis: A Prospective Multicenter Cohort (MOSAIK) studyECCO'24Year: 2024
Authors: Hyun, H.K.(1)*;Kim, J.W.(2);Lee, J.(3);Jeen, Y.T.(4);Kim, T.O.(5);Kim, J.S.(6);Park, J.J.(7);Hong, S.(8);Park, D.I.(9);Kim, H.S.(10);Lee, Y.(11);Jung, E.S.(12);Kim, Y.(12);Jung, S.Y.(12);Cheon, J.H.(7);
(1)Yonsei University College of Medicine- Yongin Severance Hospital, Department of Internal Medicine, Yongin, Korea- Republic Of;(2)SMG-SNU Boramae Medical Center- Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of;(3)Chosun University Hospital, Department of Internal Medicine, Gwangju, Korea- Republic Of;(4)Korea University Anam Hospital, Department of Internal Medicine, Seoul, Korea- Republic Of;(5)Inje University Haeundae Paik Hospital, Department of Internal Medicine, Busan, Korea- Republic Of;(6)Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(7)Yonsei University College of Medicine- Severance Hospital, Department of Internal Medicine, Seoul, Korea- Republic Of;(8)Samsung Medical Center, Department of Internal Medicine, Seoul, Korea- Republic Of;(9)Kangbuk Samsung Hospital, Department of Internal Medicine, Seoul, Korea- Republic Of;(10)Yonsei University Wonju College of Medicine, Department of Internal Medicine, Wonju, Korea- Republic Of;(11)Keimyung University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(12)Janssen Korea Ltd, Medical Affairs, Seoul, Korea- Republic Of;
P632: Isolation of a novel metalloproteinases transcriptional signature with robust anti-TNF therapy predictive power in patients with Ulcerative Colitis.ECCO'24Year: 2024
Authors: Arosa García, L.(1)*;Camba-Gómez, M.(1);Calviño-Suárez, C.(2);Bastón-Rey, I.(2);Ferreiro-Iglesias, R.(2);Porto, M.(2);Nieto, L.(2);Domínguez-Muñoz, J.E.(2);Barreiro-de Acosta, M.(2);Conde-Aranda, J.(1);
(1)Health Research Institute of Santiago de Compostela, Molecular and Cellular Gastroenterology, Santiago de Compostela, Spain;(2)University Hospital of Santiago de Compostela, Department of Gastroenterology and Hepatology, Santiago de Compostela, Spain;
P633: First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma PatientsECCO'24Year: 2024
Authors: Balyan, R.(1)*;Ghibellini, G.(1);Sunzel, E.M.(1);Dreymann, J.(2);Radivojevic, A.(3);Dotan, O.(2);Angeles, T.(1);Li, S.(1);Papp, A.(4);Rasamoelisolo, M.(1);Rabinovich-Guilatt, L.(2);
(1)Teva Branded Pharmaceutical Products, Research and Development, West Chester PA, United States;(2)Teva Pharmaceutical Industries Ltd.-, Research and Development, Netanya, Israel;(3)intiGROWTH, Llc, Miami FL, United States;(4)Teva Pharmaceutical Industries Ltd.-, Research and Development, Debrecen, Hungary;
P634: Durability of a second-line anti-TNFɑ agent compared to a different mechanism of action after first anti-TNFɑ failure in ulcerative colitis: CambiaCU StudyECCO'24Year: 2024
Authors: López-Vico, M.(1)*;Hernández-Martínez, Á.(2);Soto-Escribano, P.(3);Rojas-Feria, M.(4);Cornejo-Jiménez, A.(4);Caballero-Mateos, A.M.(5);Trapero-Martínez, A.M.(6);Sánchez-Capilla, A.D.(7);Cabello-Tapia, M.J.(7);Martín-Rodríguez, M.D.M.(7);
(1)Virgen de las Nieves University Hospital, Gastroenterology and Hepatology, Granada, Spain;(2)Hospital Universitario Torrecárdenas, Gastroenterology Unit, Almería, Spain;(3)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(4)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(5)Hospital Santa Ana de Motril, Gastroenterology Unit, Motril, Spain;(6)Hospital Universitario de Jaén, Gastroenterology Unit, Jaén, Spain;(7)Hospital Universitario Virgen de la Nieves, Gastroenterology Unit, Granada, Spain;
P635: Intravenous albumin infusion does not augment the response rate to a combination of exclusive enteral nutrition and intravenous steroids in Acute Severe Ulcerative Colitis: a randomized controlled trialECCO'24Year: 2024
Authors: Mundhra, S.(1)*;Madan, D.(1);Golla, R.(1);Sahu, P.(1);K Vuyyuru, S.(1);Kante, B.(1);Kumar, P.(1);Matthew, D.(1);Prasad, S.(1);Vaishnav, M.(1);Verma, M.(1);Virmani, S.(1);Bajaj, A.(1);Markandey, M.(1);Kumar Ranjan, M.(1);Arora, U.(1);Kumar Singh, M.(1);K Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences- New Delhi, Gastroenterology, New Delhi, India;
P636: Comparison of the real-world efficacy of filgotinib with tofacitinib in patients with refractory ulcerative colitis: A single-center retrospective studyECCO'24Year: 2024
Authors: Yagi, S.(1)*;Fukui, H.(1);Yokoyama, K.(1);Kaku, K.(1);Takagi, Y.(1);Ikenouchi, M.(1);Sato, T.(1);Kawai, M.(1);Kamikozuru, K.(1);Yokoyama, Y.(1);Tomita, T.(1);Shinzaki, S.(1);
(1)Hyogo Medical University, Department of Gastroenterology- Faculty of Medicine, Nishinomiya, Japan;
P637: Ozanimod efficacy with or without concomitant corticosteroids in 5-ASA–exposed, advanced therapy–naive, immunomodulator-naive patients with ulcerative colitis: a post hoc analysis of True NorthECCO'24Year: 2024
Authors: Horst, S.(1)*;Fischer, M.(2);Kinnucan, J.A.(3);Sauk, J.S.(4);Wu, H.(5);Jain, A.(5);Ahmad, H.A.(5);Osterman, M.T.(5);Rosen, M.(5);Sands, B.E.(6);
(1)Vanderbilt University Medical Center, Gastroenterology- Hepatology- and Nutrition, Nashville, United States;(2)Indiana University School of Medicine, Gastroenterology and Hepatology, Indiana, United States;(3)Mayo Clinic, Gastroenterology and Hepatology, Jacksonville, United States;(4)UCLA Center for Inflammatory Bowel Diseases, Gastroenterology, Los Angeles, United States;(5)Bristol Myers Squibb, n/a, Princeton, United States;(6)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
P638: Efficacy of Induction upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn’s DiseaseECCO'24Year: 2024
Authors: Chen, M.(1)*;Gao, X.(2);Cao, Q.(3);Zhang, X.(4);Chen, Y.(5);Hou, X.(6);Zhong, J.(7);Sun, Y.(8);Phaleng, X.(9);
(1)The First Affiliated Hospital- Sun Yat-sen University, Division of Gastroenterology, Guangzhou, China;(2)The Sixth Affiliated Hospital- Sun Yat-sen University, Division of Gastroenterology, Guangzhou, China;(3)Sir Run Run Shaw Hospital- Medical School Zhejiang University, Division of Gastroenterology, Hangzhou, China;(4)Nanjing Drum Tower Hospital, Division of Gastroenterology, Nanjing, China;(5)The second Affiliated Hospital of Zhejiang University, Division of Gastroenterology, Hangzhou, China;(6)Union Hospital Tongji Medical College Huazhong University, Division of Gastroenterology, Wuhan, China;(7)Ruijin Hospital- Shanghai Jiaotong University School of Medicine, Division of Gastroenterology, Shanghai, China;(8)Abbvie, Medical Affairs, Shanghai, China;(9)Abbvie, Medical Affairs, Gauteng, South Africa;
P639: Tofacitinib induces clinical remission in patients with chronic pouchitisECCO'24Year: 2024
Authors: de Jong, D.C.(1)*;Goetgebuer, R.(1);Müskens, B.(1);Neefjes-Borst, A.(2);Gecse, K.(1);Löwenberg, M.(1);de Jonge, W.(3);Bemelman, W.(4);Ponsioen, C.(1);D@E@Haens, G.(1);Duijvestein, M.(5);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Pathology, Amsterdam, The Netherlands;(3)Tytgat Institute for Liver and Intestinal Research, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Amsterdam UMC, Department of Surgery, Amsterdam, The Netherlands;(5)Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;
P640: Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective studyECCO'24Year: 2024
Authors: Falzone, M.H.(1)*;Ribaldone, D.G.(1);Saracco, G.M.(1);Bertani, L.(2);Ceccarelli, L.(2);Costa, F.(2);Bottari, A.(3);Fornaroli, G.(3);Cusato, J.(4);D@E@Avolio, A.(4);Palermiti, A.(4);Antonucci, M.(4);
(1)University of Turin, Department of Medical Sciences, Turin, Italy;(2)University Hospital of Pisa, Department of General Surgery and Gastroenterology, Pisa, Italy;(3)University of Pisa, Gastroenterology Unit, Pisa, Italy;(4)University of Turin, Laboratory of Clinical Pharmacology and Pharmacogenetics- Department of Medical Sciences, Turin, Italy;
P641: Faecal calprotectin determines non-response to corticosteroids in patients with immune checkpoint inhibitor colitisECCO'24Year: 2024
Authors: Crothers-Stomps, L.(1);Kuo, H.(2)*;Teh, W.X.(2);White, L.(2);Mohsen, W.(1);Kakkadasam Ramaswany, P.(1);Mason, R.(3);Dzienis, M.(3);Patrick, D.(2);
(1)Gold Coast University Hospital, Gastroenterology, Gold Coast, Australia;(2)Sunshine Coast University Hospital, Gastroenterology, Sunshine Coast, Australia;(3)Gold Coast University Hospital, Oncology, Gold Coast, Australia;
